Methodology
How We Identify Mispriced Opportunities in Biotech and Longevity
Most investors evaluate companies based on what they do.We evaluate them based on whether the market understands them yet.The scoring system used across this site is designed to identify mispricing—the gap between real progress and market recognition. That gap is where the most asymmetric opportunities tend to exist.
The best opportunities rarely look obvious.They appear when a company is making real progress, but the market has not fully caught up to what that progress means.This system is built to measure that gap directly.
Each company is evaluated across three dimensions: Reality, Perception, and Expansion.These three factors determine whether a company is early, fairly valued, or mispriced.
How real is the progress?This measures how far the company has actually advanced—technically, clinically, or commercially.A low score indicates early-stage concepts or limited validation.
A high score reflects proven progress, meaningful data, or revenue and adoption.This is the foundation. Without real progress, nothing else matters.
How much of that progress is already priced in?This measures how well the market understands the company.A low score means the company is underfollowed or overlooked.
A high score means expectations are already elevated and widely recognized.This is where mispricing begins to emerge. When perception lags reality, opportunity forms.
How large can this become?This captures the company’s ability to scale beyond its initial use case.Some companies are built around a single product. Others are platforms that expand across multiple markets and applications.The greater the expansion potential, the greater the long-term upside.
Each company receives a final score based on a simple formula:Reality + Expansion – PerceptionThis produces a range from -5 to +10.A higher score indicates that real progress and future potential are not yet fully reflected in valuation.
Scores are designed to be actionable.A score above +5 indicates meaningful mispricing and is typically considered a buy opportunity, where progress is real and recognition is still limited.Scores between +3 and +5 suggest a company that is gaining traction but not fully appreciated.
These are often accumulation opportunities, where additional validation may act as a catalyst.Scores between +1 and +2 indicate a company worth watching. The story is partially understood, and future developments will determine whether it becomes more compelling.Scores near zero suggest the company is fairly valued. The market broadly understands the current state of the business.Negative scores indicate that expectations may be ahead of reality. In these cases, risk increases and caution is warranted.
This is not a price target model.It does not attempt to predict short-term movement or exact valuation outcomes.It is not a replacement for deep research.
It identifies where the market may be wrong.It highlights companies where progress is real but not fully recognized.It provides a consistent way to compare opportunities across early-stage, mid-stage, and emerging categories.
Biotech and longevity are entering a new phase.Advances in AI, biomaterials, and regenerative platforms are compressing timelines that once took decades. What was once experimental is becoming commercially viable.As this transition accelerates, the market will not reprice everything evenly.It will reprice selectively.The goal is to identify those opportunities early—before recognition catches up.
Markets are efficient at pricing what is obvious.They are far less efficient at pricing what is emerging.This system is built to find that difference.That difference is where the opportunity lives.